Meet Altos Labs, Silicon Valley’s newest wild bet to live forever
During 2021, however, a new plan has emerged to make research move more quickly by creating the idea that Altos is now a well-funded company. That effort took shape under the direction of Richard Klausner, a one -time head of the National Cancer Institute and now an entrepreneur. Klausner, who previously helped start companies like Juno Therapeutics and cancer testing companies Grail, Known for organizing large, and profitable, financial stakes in new biotechnologies.
According to a UK merger submission for Altos Labs, Klausner is CEO of the new company. Klausner did not respond to attempts to contact him via email and phone. Like Milner, he also lives in the Los Altos Hills.
Many startups are pursuing programming technology as well, including Life Biosciences, Turn Biotechnologies, AgeX Therapeutics, and Shift Bioscience in the UK, although these efforts have not yet delivered any treatments that have been tested in people with clinical trials. test.
“There are hundreds of millions of dollars raised by investors to invest in programming as well, which is specifically aimed at transforming parts or all of the human body,” said David Sinclair, a Harvard University researcher who in December reports restoration of vision in mice using the method.
Sinclair described the field as “newborn” but thought it had incredible promise. “What else can you do to change the age of the body?” according to him. “In my lab we deliver key organs and tissues, for example skin, muscles and brain-to find out who we can keep alive.” Sinclair said he was not involved in Altos but he was speaking at the 2020 meeting and applying for an award from the Milky Way.
A science business
Altos has not yet made an official announcement, but it included Delaware this year and a securities disclosure filed by California in June that showed the company had earned at least $ 270 million, according to Will Gornall, a professor of business school at the University of British Columbia reviewing the document. In addition to Bezos and Milner, the company may have more wealthy tech numbers and capitalists looking as investors.
Other hires Altos has made include Peter Walter, whose laboratory at the University of California, San Francisco, is behind a molecule that shows strange effects on memory. Also in attendance was Wolf Reik, a reprogramming specialist who recently resigned as director of the Babraham Institute in the UK after the center. SAYS he carried out a job “with another research organization” now believed to be Altos. Walter and Reik declined to comment.
At least initially, Altos will fund researchers with no immediate anticipation for products or revenue. According to someone Klausner and Milner, the company’s preliminary exit would be “good science.”
Altos lured university professors by offering the sports-star a salary of $ 1 million a year or more, including equity, as well as freedom from the hassle of applying for grants. A researcher who has confirmed receiving a job offer from Altos, Manuel Serrano of the Institute for Research in Biomedicine, in Barcelona, Spain, says the company will pay him five to 10 times his current income.
“The philosophy at Altos Labs is to do research driven by curiosity. This is what I know how to do and want to do,” said Serrano, who plans to move to Cambridge, UK to join an Altos facility. there. In this case, through a private company, we have the freedom to be bold and analyze. In this way I can change. “
Any treatment for a major disease of aging could cost billions, but Altos doesn’t rely on making money first. “The goal is to understand rejuvenation,” Serrano said. “I’d say the idea that we have a future is already there, but it’s not the immediate goal.”